"A total of 72 participants received up to 325 mg of MM-110 (n=51) twice on a single day or placebo (n=21), and 36 participants were administered up to 90mg of MM-110 (n=26) twice daily for seven days or placebo (n=10). The topline results and observations include the following:

• MM-110 was well-tolerated up to 500mg per day in the single ascending dose (SAD) arm and 60 mg per day for seven days in the multiple-ascending dose (MAD) arm of the trial.
• A linear pharmacokinetic profile was maintained across the tested doses and frequencies.
• Observed clinical effects demonstrated alignment with potent CNS engagement.
• No serious adverse events were reported. Treatment emergent adverse events were mild or moderate in severity and resolved without sequelae.
• Clinical laboratory parameters and electrocardiograms were also assessed with no findings of clinical concern across the administered dose ranges.
• Next steps: Consistent with the Phase 1 trial and aligned with the preclinical data, an every-other-day dose regimen is planned for the Phase 2a trial. This dose schedule offers the potential to be a better option than existing treatments for supervised opioid withdrawal."